Sanofi in Lockstep with US Insulin Price Cuts
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing sideward barbs at the system.
diabetic
Sanofi Buying Diabetes Specialist Provention Bio
Paris-based French drugmaker Sanofi has agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of about $2.9 billion. The publicly traded US biopharma focuses on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D).
Lilly Insulin Price Cut Revives US Discussion
As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly prescribed insulin products at the beginning of March.
